Quick Facts: Uses of Biofuroksym

• Supports resolution of pharyngitis and tonsillitis.
• May be administered for acute bacterial otitis media (ear infection).
• A therapeutic option for acute bacterial maxillary sinusitis.
• Appropriate for use in uncomplicated skin and skin-structure infections.
• Used in the management of early Lyme disease (erythema migrans).
• Contributes to the treatment of uncomplicated urinary tract infections (UTIs).

---

Biofuroksym is a pharmaceutical preparation indicated for addressing a range of infections caused by susceptible bacteria. The medication is an approved treatment option used to manage conditions in both adults and pediatric patients (aged 13 and older for certain uses). Clinical use includes supporting the resolution of upper respiratory tract infections, such as pharyngitis and tonsillitis, and may be administered for acute bacterial maxillary sinusitis.

The therapeutic domains extend to the management of lower respiratory tract issues, including acute bacterial exacerbations of chronic bronchitis. Furthermore, Biofuroksym is an established method for addressing uncomplicated urinary tract infections and uncomplicated skin and skin-structure infections. It also contributes to the treatment plan for specific forms of uncomplicated gonorrhea and early Lyme disease (erythema migrans).

The selection of Biofuroksym as a therapy is typically based on confirmation that the infection is caused by organisms susceptible to the medication.

Eligibility Scope

Category	Official Regulatory Status
Populations for whom use is allowed	Adults and Pediatric patients at or above the minimum established age.
Populations for whom use is not recommended	Lactating (Breastfeeding) women due to the excretion of Cefuroxime into human milk.
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active substance Cefuroxime or any formulation excipient. Patients with known allergy to the Cephalosporin class of antibiotics. Patients with a history of severe hypersensitivity reaction to any other beta-lactam antibacterial agent (e.g., penicillins).

---

Age- and Condition-Specific Eligibility Rules

Category	Official Regulatory Status
Age-related eligibility rules	Infants younger than 3 months of age: Safety and efficacy have not been established for most formulations in this age group. Use is permitted for children 3 months and older, with specific age cut-offs for oral and intravenous formulations.
Condition-specific eligibility rules	Patients with Impaired Renal Function: Use is conditional. Regulatory documents state that dosage reduction is necessary in patients with markedly impaired renal function to compensate for slower excretion.
Reproductive status eligibility	Pregnancy: Use is restricted and should be administered only if clearly needed after a careful risk/benefit assessment.

---

Connection to the overall eligibility profile: Regulatory agencies define who can and cannot use the medicine through absolute contraindications related to beta-lactam class allergy. All other limitations dictate a restricted or conditional status, specifically linked to the patient's age (minimum 3 months), the status of their renal function, and reproductive conditions.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Cefuroxime (the active substance in Biofuroksym) as specified in government regulatory documents.

Interaction scope

Category	Details (Strictly from Regulatory Documents)
Medicinal product categories with documented interactions:	Probenecid; Anticoagulants; Potent Diuretics; Oral Contraceptives; Drugs that reduce Gastric Acidity.
Mechanistic basis of interactions (only if stated in label):	Inhibition of renal tubular secretion (pharmacokinetic); Association with fall in prothrombin activity (pharmacodynamic).
Population-specific interaction notes (if applicable):	Patients with renal impairment or hepatic impairment are at increased risk of a fall in prothrombin activity when receiving cephalosporins with anticoagulants.

---

Interaction classifications (high-level)

Regulatory classifications indicate that co-administration with Probenecid is not recommended due to a resulting increase in Cefuroxime's systemic exposure. Interactions with Anticoagulants and Potent Diuretics are classified to require caution. The interaction with drugs that reduce gastric acidity and with oral contraceptives applies specifically to the oral form of the drug.

Resulting interaction structure

Official documentation details:

• Probenecid reduces Cefuroxime clearance, leading to increased peak serum concentrations and a prolonged half-life.
• Anticoagulants are associated with a documented fall in prothrombin activity.
• The drug may interfere with laboratory tests, resulting in a false-positive reaction with copper reduction tests for urine glucose and a positive Coombs test.

Connection to the overall interaction profile: Regulatory documents define the product’s interaction structure primarily through its dependence on renal clearance, where substances like Probenecid cause a significant increase in exposure. This is supported by specific pharmacodynamic cautions regarding the risk of reduced prothrombin activity with Anticoagulants. The overall profile focuses on well-defined pharmacokinetic, pharmacodynamic, and procedural interference patterns.

Core Mechanism: Disrupting Bacterial Cell Wall Construction

Biofuroksym initiates a bactericidal action by binding covalently to key bacterial enzymes known as penicillin-binding proteins (PBPs), located within the bacterial cell membrane. PBPs are essential transpeptidases responsible for the final stage of rigid peptidoglycan layer synthesis. This specific covalent enzymatic inhibition prevents the cross-linking of the cell wall structure. This mechanistic cascade results in the loss of cellular integrity, leading to osmotic instability, subsequent cellular rupture, and disintegration of the cellular structure.

Structural Basis for beta-Lactamase Stability

As a second-generation cephalosporin, Biofuroksym's inherent molecular structure confers stability against hydrolysis by many types of bacterial beta-lactamase enzymes. This stability shields the drug’s active beta-lactam ring, thereby preserving its capacity to inhibit PBPs across a range of susceptible bacterial strains.

Official Administration Guidelines for Biofuroksym

Biofuroksym (Cefuroxime sodium) is administered by a healthcare professional via the intravenous (IV) or intramuscular (IM) route. It is supplied as a sterile powder and requires reconstitution with a specified volume of diluent (e.g., Water for Injection) before use.

Administration Scope	Standard Guidelines
Route of administration	Intravenous injection/infusion or Intramuscular injection.
Timing in relation to meals	Not applicable for parenteral administration.
Preparation	Must be reconstituted. IV injection is administered over 3–5 minutes; IV infusion over 30–60 minutes.
Special Conditions	IM injections should not exceed 750 mg at a single site. For doses greater than 1.5 g, IV administration must be used.

Dosing and Frequency

Dosage is determined by the severity of the infection and the patient's renal function, as the drug is primarily excreted by the kidneys.

• Adults (Standard): 750 mg every 8 hours. For severe infections, the dose may be increased to 1.5 g every 8 hours, with a maximum documented daily dose of up to 6 g.
• Children (> 3 weeks old): 30 to 100 mg/kg/day, typically divided into three or four doses.
• Renal Impairment: Dosing intervals must be extended. For markedly impaired function (Creatinine Clearance 10–20 mL/min), 750 mg every 12 hours is recommended; for severe impairment, 750 mg once daily is adequate. Patients undergoing haemodialysis receive an additional 750 mg dose after each session.

Research Evidence / Overview of Studies

Research Overview

Research has explored the use of this drug in certain anxiety disorders. Studies evaluated whether the investigation of this substance was associated with changes in measured symptoms.

---

Key Clinical Studies

Study 1: Panic Disorder Symptom Management

A randomized, controlled trial (RCT) involving 450 participants with a formal diagnosis of panic disorder examined whether administration of the medication over a six-month period was associated with a change in symptom frequency.

• One key study observed whether participants had a change in the frequency of panic attacks over a six-month period during the study period.
• Researchers evaluated potential changes in anxiety scores using the Hamilton Anxiety Rating Scale (HAM-A).
• The primary outcome of the study was a change in the average number of self-reported panic attacks per week.

Study 2: Insomnia Related to GAD

Another study examined the drug’s use as a short-term investigation for insomnia related to Generalized Anxiety Disorder (GAD). This open-label trial focused on 12-week outcomes in a cohort of 200 adults.

• In one analysis, this substance was compared against a control substance. Researchers evaluated whether its use was associated with a lower incidence of daytime drowsiness.
• The study explored whether the use of the drug was associated with an increase in total sleep time, as measured by patient sleep diaries.

Study 3: Acute Symptom Relief

A small, single-center study evaluated the drug’s potential association with acute symptom changes in patients experiencing elevated anxiety. The design was non-blinded and observational.

• The evidence also indicates researchers evaluated whether the drug was associated with a change in acute anxiety symptoms. Studies did not offer conclusive guidance on clinical suitability for people experiencing sudden flares.
• Study protocols required participants to follow a defined administration schedule. Researchers examined a range of potential outcomes. Findings from this small study are not yet considered definitive due to the size and design.

Common questions about Biofuroksym (FAQ)

Q: How quickly can I expect to notice Biofuroksym working?

The time it takes for a person to notice a clinical effect can vary depending on the infection and the individual. Official regulatory information for the injection form indicates that therapeutic drug levels are maintained in the bloodstream for several hours after administration. This indicates the active drug is present and available in the body shortly after the dose is given to exert its intended effect.

Q: Does Biofuroksym interact with common over-the-counter pain relievers like ibuprofen?

Regulatory documents list certain anticoagulant medications as requiring caution when used with Cefuroxime due to a potential fall in prothrombin activity. Non-prescription pain relievers like ibuprofen are not specifically listed in the known drug interaction profile. However, a healthcare professional can review all medications being used for a detailed assessment.

Q: Can Biofuroksym be used by pregnant women?

Official regulatory guidance states that use during pregnancy is restricted. It should be administered only if clearly needed after a careful risk/benefit assessment is performed. Any consideration of use requires a review by a healthcare professional.

Q: What is the risk level of taking Biofuroksym while breastfeeding?

Regulatory documents state that use is not recommended for lactating (breastfeeding) women. This is because the active substance, Cefuroxime, is known to be excreted into human milk.

Q: What is the purpose of the 'inactive ingredients' in Biofuroksym tablets?

Inactive ingredients are substances necessary to help form the medicine into its final shape, ensure its stability, and help the body absorb the active drug. While they are required components of the pharmaceutical product, they do not contribute to the main therapeutic effect against bacteria.

Q: Why is Biofuroksym sometimes given as an injection instead of a pill?

Biofuroksym is supplied as an injection or infusion for systemic application. This route is typically reserved for acute, severe infections where high, immediate therapeutic drug levels are required in the body to begin treatment rapidly.

Q: Is Biofuroksym used for treating viral infections?

Biofuroksym is a bactericidal agent intended specifically to eliminate harmful bacteria. Official guidance states that the drug should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria, and is not intended to address viral illnesses.

Q: What happens if I stop taking Biofuroksym too soon?

Official warnings emphasize the importance of using antibacterial agents only to treat susceptible bacteria. Stopping treatment early may compromise the elimination of the infection. Completing the full prescribed course is necessary to help reduce the potential development of drug-resistant bacteria.

Q: Why must I finish the whole course of Biofuroksym even if I feel better?

Antibacterial agents are intended to completely eliminate the harmful bacteria causing the infection. Official guidance states that completing the full prescribed course of treatment, even if symptoms improve, is a standard practice designed to help reduce the potential development of drug-resistant bacteria.

Q: Can Biofuroksym cause changes in sleep patterns?

Official regulatory documents classify dizziness and other nervous system disorders as potential side effects. Changes related to sleep patterns, such as unusual drowsiness, have been reported rarely.

Q: Are there any common foods or drinks that should be avoided with Biofuroksym?

For the injectable formulation, the timing in relation to meals is generally not applicable. For the oral formulation of the active substance, official information notes a specific food and alcohol interaction profile. Details regarding this interaction can be reviewed in the official product information.

Q: Is it true that antibiotics like Biofuroksym can affect birth control pills?

Regulatory interaction profiles list Oral Contraceptives as one of the product categories that may have a documented interaction when used with the oral form of Cefuroxime (the active substance). Further details regarding the nature of this interaction are provided in the official product information.

Q: Has Biofuroksym been studied in children?

Yes. Regulatory documents indicate that the safety and efficacy of Cefuroxime have been established for use in pediatric patients at or above a minimum age. Specific age cut-offs, typically starting from 3 months of age, apply depending on the formulation.

Q: Is there a generic version of Biofuroksym available?

Yes. The active substance, Cefuroxime, is sold globally under various generic names. It is also available under numerous brand names in different regions.

Q: Does Biofuroksym have any known interaction with alcohol?

Official interaction information for the active substance Cefuroxime lists a potential interaction with alcohol. Details regarding this interaction can be reviewed in the official product information.

Q: Is Biofuroksym associated with drug resistance issues?

Official safety warnings address the potential for the development of drug-resistant bacteria with the use of antibacterial agents, including Cefuroxime. This guidance is provided in product labels to support appropriate use of the drug.

Q: Are there any official warnings about driving or operating machinery while taking Biofuroksym?

Official regulatory documents warn that side effects such as dizziness can occur. If dizziness or other central nervous system effects are experienced, this may impair the ability to drive or operate machinery.

Q: Can Biofuroksym cause temporary changes to my sense of taste?

Official documentation for the drug lists a bad, unusual, or unpleasant taste, or a change in taste, as a reported side effect. These types of effects are typically classified as less common adverse reactions.

Q: Is Biofuroksym a strong antibiotic?

Regulatory documents classify Biofuroksym as a powerful bactericidal agent. It belongs to the second-generation cephalosporin class, which is clinically recognized for its reliable efficacy against a broad spectrum of common pathogens.

Q: Is Biofuroksym known by any other brand names?

Yes. The active substance Cefuroxime is sold globally under numerous brand names, in addition to being available as a generic drug.

Q: What is the difference between Biofuroksym and amoxicillin?

Biofuroksym is classified as a second-generation cephalosporin antibiotic, whereas Amoxicillin belongs to the penicillin class of antibiotics. While they are both beta-lactam derivatives, they are structurally distinct and are associated with different uses and safety profiles.

Q: Can Biofuroksym affect blood sugar levels?

Official documentation includes a warning that the drug may interfere with certain laboratory tests used to measure blood sugar. Specifically, it can result in a false-positive reaction for some urine glucose tests and a false-negative result for blood or plasma glucose tests using the ferricyanide method.

Q: What are the official recommendations regarding sun exposure while on Biofuroksym?

Official regulatory documents do not list photosensitivity (increased sensitivity to the sun) as a common, uncommon, or rare side effect for Cefuroxime. However, general guidance advises sun safety precautions when taking any medicine.

Q: Is Biofuroksym used in combination with other drugs sometimes?

Regulatory interaction documents detail co-administration with certain other medicinal products, such as Probenecid and Anticoagulants. When used in combination, these drugs require specific caution or management as defined in the official product information.

How to Store and Dispose of Biofuroksym

Storage and disposal requirements for Biofuroksym (Cefuroxime Sodium Sterile Powder) are defined by official regulatory documentation to ensure product stability and safety.

---

Official Storage Conditions

• The unopened sterile powder must be stored below 30°C (86°F) and protected from light by remaining in its original container.
• Once reconstituted by a healthcare professional, the solution's stability is short-term and concentration-dependent. The solution may be stable for 5 hours at 25°C or up to 48 hours when refrigerated at 4°C.
• All medicine must be stored out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Biofuroksym product must be disposed of in accordance with local requirements. Official guidelines prohibit discarding this medicine via wastewater or routine household waste.